Serpin inhibitors for the treatment of prion and prion like diseases - License agreements and joint venture opportunity
A research group based in Italy has developed a new class of small molecules acting as SERPINA3 inhibitors, which are able to reduce prion protein (PrPSc) accumulation in prion-infected cell lines, thereby representing a new therapeutic treatment against prion and prion-like diseases. They are looking for licence agreements and joint venture agreements with pharma companies and/or financial agreements with investors.
Pharma Companies/Investors interested in acquiring and co-developing the technology.
To date, despite numerous active efforts, there are no drugs available for the cure of the neurodegenerative diseases collectively referred as prion and prion-like disorders. Symptomatic treatment is the only available option, including the administration to patients of antipsychotics, such as quetiapine and clonazepam, to treat myoclonus, and of selective serotonin re-uptake inhibitors (SSRIs) to treat depression. Indeed, through this invention, the technology transfer office of a research center based in the North of Italy and internationally renowned, is presenting a new class of small molecules. These small molecules are acting as SERPINA3 inhibitors, which are able to reduce PrPSc accumulation in prion-infected cell lines, thereby representing a new therapeutic treatment against prion and prion-like diseases. The development of specific inhibitors of SERPINA3 with an activity in the nanomolar range is expected. The characterization of structural models of the binding of the small molecules with the protein should allow the identification of novel inhibitors with improved potency. The research center is looking for licence agreements or joint ventures with industry (pharma companies) or financial agreements with investors interested in developing new drugs.
Advantages and innovations
So far there are no effective therapies for prion diseases. The proposed technology aims at developing novel molecules with improved efficacy on these diseases.
Under development/lab tested
Intellectual Property Rights (IPR)
Patent(s) applied for but not yet granted
Register your interest
How it works
- Tell us about yourself
- We’ll discuss with you
- We put the right partners in touch
EEN help you find the right partner, rather than you going it alone.
Our role is to review and collate the most suitable submissions, and then send them to the client who posted the opportunity. We consult with you, and the client, to make the process professional and easy.
These are live opportunities. Your registration of interest on the site is just like a professional approach to a business at a networking event. To stand the best chance of success, make your submission really sing. Sell why the client who posted the opportunity should work with you. Excite them. Ask questions. Try and avoid copy and pasting words from elsewhere.
Once the client has chosen their partner, we'll introduce them over email and keep in touch with both parties to see how it's going. Sometimes things progress quickly. Sometimes because of changing priorities for either party, things progress slowly, but you never know - your next big business break could start right here.
First we need to check you’re human.
Thank you for verifying your email. We have sent you a confirmation email containing a 6 digit verification code to unlock the form below